HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Dr. Reddy's Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Dr. Reddy's Intelligence Report

Generated from 6 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jul 21, 2026

Confidence

Moderate Confidence · 76%

Evidence

36 items

Sources

12

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Dr. Reddy's maintains an active intelligence profile across Hematology, Vitamin K, Oncology, BCL-2 Inhibitor, Chemotherapy. 6 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 76% across 3 tracked sources. Highest-priority development: FDA AP — LITHIUM CARBONATE (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Dr. Reddy's; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — LITHIUM CARBONATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — PREDNISONE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Verified Clinical Benefit | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    CDER proposes to withdraw approval of TAVNEOS

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Verified Clinical Benefit | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Withdrawn | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Notice: Register of authorised online sellers of medicines in Northern Ireland

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 256 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — LITHIUM CARBONATE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PREDNISONE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • CDER proposes to withdraw approval of TAVNEOS

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Notice: Register of authorised online sellers of medicines in Northern Ireland

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA AP — PREDNISONE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — CAPECITABINE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Dr. Reddy's Venetoclax ANDA214733

    Oncology · BCL-2 Inhibitor

  • FDA Grants AP Status for Dr. Reddy's Capecitabine ANDA204345

    Oncology · Chemotherapy

  • FDA Grants AP Status for Dr. Reddy's PHYTONADIONE ANDA215820

    Hematology · Vitamin K

  • FDA Approval Update for Omeprazole ANDA207740 by Dr. Reddy's

    Gastroenterology · Proton Pump Inhibitor

  • FDA Grants Approval for Prednisone ANDA218035 by Dr. Reddy's

    Endocrinology · Corticosteroid

  • FDA Accepts Supplement Application for Lenalidomide by Dr. Reddy's

    Oncology · Small Molecule

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.